Angiotensin-II receptor blockers or angiotensin converting enzyme inhibitors for the treatment of hypertension amid COVID-19 pandemic

Expert Rev Cardiovasc Ther. 2021 Jan;19(1):99-100. doi: 10.1080/14779072.2021.1842050. Epub 2020 Nov 12.

Authors

Chia Siang Kow¹, Syed Shahzad Hasan^{2

3}

Affiliations

¹ School of Postgraduate Studies, International Medical University , Kuala Lumpur, Malaysia.
² Department of Pharmacy, University of Huddersfield , Huddersfield, United Kingdom.
³ School of Biomedical Sciences & Pharmacy, University of Newcastle , Callaghan, Australia.

PMID: 33112190
DOI: 10.1080/14779072.2021.1842050

No abstract available

Publication types

Editorial
Comment

MeSH terms

Angiotensin Receptor Antagonists / therapeutic use
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Angiotensins / pharmacology
Antihypertensive Agents / therapeutic use
COVID-19*
Humans
Hypertension* / drug therapy
Hypertension* / epidemiology
Pandemics
Renin-Angiotensin System / drug effects
Risk Management
SARS-CoV-2

Substances

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Angiotensins
Antihypertensive Agents